Study warns of nutrient deficiencies in children using GLP-1 weight-loss drugs
Researchers at Northwestern University found that children and teens treated with GLP-1 medications may develop nutritional shortfalls, prompting calls for closer medical monitoring.
A team of scientists from Northwestern University reviewed a large database of pediatric patients who began GLP-1-based treatments such as Ozempic between 2017 and 2022. Among about two thousand children and adolescents aged 10-17 with no prior nutrient deficiencies, a noticeable share later showed signs of vitamin D shortage, iron-deficiency anemia or related conditions within a year of starting the medication. The study, appearing in Childhood Obesity, emphasizes that while GLP-1 drugs are effective for obesity and type-2 diabetes, their impact on nutrition in young users remains insufficiently understood.
Researchers recommend that healthcare providers monitor nutritional markers regularly for this population. The World Health Organization highlights the broader context of rising childhood obesity worldwide, which increases long-term health risks.
Why it matters
Children on popular weight-loss drugs may face hidden nutrient gaps, affecting their health and requiring vigilant medical oversight.
In this story
